| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Samuel O'Rear last filed a Form 4 in May 2023, as Director at SRTS. Samuel O'Rear's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Samuel O'Rear a strong insider score of 77/100, based on 4 past trades. Over a 12-month horizon, all 4 of those trades were profitable, with an average 12-month return of +52.0%.
At the last filing, the largest reported position was 143,570 shares of SRTS. The SRTS filings lean toward selling, a net 30,000 shares.
Samuel O'Rear has 5 Form 4 filings on record from July 2016 to May 2023, all as Director at Sensus Healthcare (SRTS), 2016–2023.
The 7 reported transactions were 2 open-market purchases, 2 open-market sales, 2 stock awards and 1 other transaction.
Counted by filing, the open-market trades come to 1 purchase worth about $60K and 1 sale worth about $710K.
The only open-market purchase was 20,000 shares of SRTS at an average $2.99 on May 9, 2023, about $60K. Twelve months later SRTS was up 33%.
The only open-market sale was 50,000 shares of SRTS at an average $14.20 on August 10, 2022, about $710K. Twelve months later SRTS was down 76%.
Shares as reported in the last Form 4 for each company; the most recent is from May 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.